Seven low-mass ions in pretreatment serum as potential predictive markers of the chemoradiotherapy response of rectal cancer.

abstract：:The in-vitro growth inhibition of cancer and normal cell lines caused by mixed or covalently linked antimetabolites should clarify whether the conjugation of antimetabolites influences cell sensitivity and growth inhibition in a manner that differs from an equimolar mixture of the same antimetabolites or not. Growth i...

journal_title：Anti-cancer drugs

authors： Weinreich J,Struller F,Küper M,Hack A,Königsrainer A,Schott TC

更新日期：2013-04-01 00:00:00

abstract：:We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib. The serum levels of sP-selectin and TxB2 increased significantly in all patients who received gefitinib...

journal_title：Anti-cancer drugs

authors： Kanazawa S,Yamaguchi K,Kinoshita Y,Muramatsu M,Komiyama Y,Nomura S

更新日期：2006-04-01 00:00:00

abstract：:The aim of this paper was to investigate whether sinoporphyrin sodium (DVDMS) could be a novel sonosensitizer in sonodynamic therapy. We used two kinds of leukemia cells (K562, U937) as main tumor cell models and cells (peripheral blood mononuclear cells, spleen lymphocytes) separated from healthy ICR mice as normal c...

journal_title：Anti-cancer drugs

authors： Hu J,Wang X,Zhang K,Wang P,Su X,Li Y,Huang Z,Liu Q

更新日期：2014-02-01 00:00:00

abstract：:Taxol is an antitumor drug which, as its mechanism of action, promotes microtubule assembly in vitro. Camptothecin (CPT) is an anticancer agent with the peculiar mechanism of poisoning eukaryotic DNA topoisomerase I. Both drugs are in clinical trials and their chemotherapeutic efficacy seems promising in refractory hu...

journal_title：Anti-cancer drugs

authors： Debernardis D,Cimoli G,Parodi S,Russo P

更新日期：1996-07-01 00:00:00

abstract：:Thirty-three patients with advanced and refractory breast cancer were treated with two mitoxantrone-containing regimens (mitoxantrone plus mitomycin and mitoxantrone plus mitomycin plus methotrexate). All patients had received previous chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF); cyclophosp...

journal_title：Anti-cancer drugs

authors： Astone A,Cassano A,Fontana T,Noviello MR,Pozzo C,Barone C

更新日期：1992-10-01 00:00:00

abstract：:The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in patients receiving topotecan to optimize the clinical management of topotecan hematotoxicity. Twenty-one advanced ovarian cancer patients, all pretreated with cispla...

journal_title：Anti-cancer drugs

authors： Goldwasser F,Buthaud X,Gross M,Bleuzen P,Cvitkovic E,Voinea A,Jasmin C,Romain D,Misset JL

更新日期：1999-03-01 00:00:00

abstract：:Gossypol [(2,2'-binaphthalene)-8,8'-dicarboxaldehyde-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl] 1a is a naturally occurring compound extracted from the cotton plant and has been extensively studied as an oral male contraceptive. Its favorable toxicity profile, and the more recent demonstration of anti-...

journal_title：Anti-cancer drugs

authors： Shelley MD,Hartley L,Groundwater PW,Fish RG

更新日期：2000-03-01 00:00:00

abstract：:Our previous studies have shown that arsenic trioxide (As2O3), a novel anti-cancer agent, may be active against urothelial carcinomas. A series of bladder urothelial carcinoma cells with progressive As2O3 resistance were established and studied to reveal molecular events in relation to the mechanisms of resistance to ...

journal_title：Anti-cancer drugs

authors： Hour TC,Huang CY,Lin CC,Chen J,Guan JY,Lee JM,Pu YS

更新日期：2004-09-01 00:00:00

abstract：:Long noncoding RNA (lncRNA) KTN1 antisense RNA 1 (KTN1-AS1) is a novel promoter in the progression of some cancers. However, the knowledge of its role in lung adenocarcinoma is still limited. The current study aimed to examine the biological functions of KTN1-AS1 and its coexpressed protein in lung adenocarcinoma. The...

journal_title：Anti-cancer drugs

authors： Li YY,Li W,Chang GZ,Li YM

更新日期：2021-01-22 00:00:00

abstract：:Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liq...

journal_title：Anti-cancer drugs

authors： Liu Z,Liang C,Zhang Z,Pan J,Xia H,Zhong N,Li L

更新日期：2015-11-01 00:00:00

abstract：:1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

journal_title：Anti-cancer drugs

authors： Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

更新日期：2000-06-01 00:00:00

abstract：:In our institution, 103 glioblastoma multiforme (GBM) patients aged from 55 to 83 years were treated since November 1994 as follows. All patients underwent surgical intervention (gross total resection, n = 35; subtotal resection, n = 38; stereotactic biopsy, n = 30). Subsequently all patients were offered radiotherapy...

journal_title：Anti-cancer drugs

authors： Piribauer M,Fazeny-Dörner B,Rössler K,Ungersböck K,Czech T,Killer M,Dieckmann K,Birner P,Prayer D,Hainfellner J,Muhm M,Marosi C

更新日期：2003-02-01 00:00:00

abstract：:Ecteinascidin 743 (Et743) is an interesting compound in phase II/III clinical trials. Its chemistry is complex, its mechanism of action is original and it is active in human cancers, such as sarcomas refractory to conventional chemotherapy. The present review describes the discovery of the drug, its specific interacti...

journal_title：Anti-cancer drugs

authors： Aune GJ,Furuta T,Pommier Y

更新日期：2002-07-01 00:00:00

abstract：:This multi-center trial was carried out to assess the therapeutic potential of recombinant tumor necrosis factor (rTNF) as the first form of systemic therapy for advanced carcinomas of gastric and pancreatic origin. To be eligible patients were required to have no overt sign of coagulopathy and hepatic function studie...

journal_title：Anti-cancer drugs

authors： Muggia FM,Brown TD,Goodman PJ,Macdonald JS,Hersh EM,Fleming TR,Leichman L

更新日期：1992-06-01 00:00:00

abstract：:Imatinib is the standard first-line therapy for metastatic gastrointestinal stromal tumors. It has markedly improved the prognosis and outcome of patients affected by gastrointestinal stromal tumors, especially in the case of exon 11 KIT mutations. Imatinib-associated adverse events are generally mild to moderate; how...

journal_title：Anti-cancer drugs

authors： Saponara M,Gatto L,Di Nunno V,Tabacchi E,Fanti S,Di Scioscio V,Nannini M,Gruppioni E,Altimari A,Fiorentino M,Santini D,Ceccarelli C,Zompatori M,Biasco G,Pantaleo MA

更新日期：2016-04-01 00:00:00

abstract：:We demonstrate that neurokinin A (NKA) and substance P (SP) play a role in the proliferation of the estrogen receptor-negative (ER-) cell line MDA-MB-231, a human breast carcinoma expressing both NK-1 and NK-2 receptors. In vitro experiments showed that the specific receptor antagonists MEN 11,467 (NK-1) and nepadutan...

journal_title：Anti-cancer drugs

authors： Bigioni M,Benzo A,Irrissuto C,Maggi CA,Goso C

更新日期：2005-11-01 00:00:00

abstract：:The aim of this study was to probe the influence of microRNA-301b (miR-301b) in esophageal cancer pathogenesis. Based on the data acquired from The Cancer Genome Atlas database, we found that miR-301b was highly expressed in esophageal cancer tissues and high expression of miR-301b was related to worse prognosis in pa...

journal_title：Anti-cancer drugs

authors： Pan F,Chen M,Song XY,Yang JD

更新日期：2020-04-01 00:00:00

abstract：:DNA has been one of the major targets of cancer chemotherapy. A variety of anti-neoplastic agents can cause different types of DNA lesions, including base alterations, single- or double-strand DNA breaks, DNA-DNA cross-links and DNA-protein cross-links. The exact processes by which these DNA lesions lead to cell death...

journal_title：Anti-cancer drugs

authors： Kubota M

更新日期：1991-12-01 00:00:00

abstract：:Amifostine is a broad-spectrum cytoprotective agent approved for protection against cisplatin toxicities and radiation-induced xerostomia; strong clinical evidence exists that amifostine protects normal mucosa and lung from radiation damage. Hypotension, nausea/vomiting, fatigue and fever/rash are the main side-effect...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Maltezos E

更新日期：2006-02-01 00:00:00

abstract：:It is well known that the anti-cancer drug cisplatin has an ototoxic property; however, the details are not yet evident. In this study, the expression of inducible nitric oxide synthase (INOS/NOS II) in the vestibule of guinea pigs after i.p. injections of cisplatin was examined immunohistochemically. Three days after...

journal_title：Anti-cancer drugs

authors： Watanabe K,Hess A,Bloch W,Michel O

更新日期：2000-01-01 00:00:00

abstract：:Schlafen-11 (SLFN11) showed a highly significant positive correlation with the response of topoisomerase inhibitors in cancer cell lines derived from prostate, lung, etc. However, this finding has not been validated in colorectal cancers (CRCs). Although irinotecan (CPT-11), a topoisomerase inhibitor, is one of the mo...

journal_title：Anti-cancer drugs

authors： Tian L,Song S,Liu X,Wang Y,Xu X,Hu Y,Xu J

更新日期：2014-11-01 00:00:00

abstract：:To devise a meaningful nutritional therapy in cancer, a greater understanding of nutritional dimensions as well as of expectations of patients and disease impact is essential. We have shown that nutritional deterioration in patients with gastrointestinal and head and neck cancer was multifactorial and mainly determine...

journal_title：Anti-cancer drugs

authors： Ravasco P

更新日期：2011-08-01 00:00:00

abstract：:We conducted a phase I study to determine the maximum tolerated dose, the recommended dose and the safety profile of S-1 and carboplatin combination regimen in the treatment of patients with advanced non-small-cell lung cancer. Chemotherapy-naive patients with advanced non-small-cell lung cancer were treated with S-1 ...

journal_title：Anti-cancer drugs

authors： Kaira K,Sunaga N,Yanagitani N,Imai H,Utsugi M,Shimizu Y,Iijima H,Tomizawa Y,Hisada T,Ishizuka T,Saito R,Mori M

更新日期：2007-04-01 00:00:00

abstract：:Norcantharidin (NCTD), a chemically modified form of cantharidin, is a potential anticancer drug. This study investigated the effect of NCTD on anoikis in CT26 colorectal adenocarcinoma cells. NCTD treatment of CT26 cells showed a dose-dependent and time-dependent decrease in viability and cell proliferation. Growth i...

journal_title：Anti-cancer drugs

authors： Chen YJ,Kuo CD,Tsai YM,Yu CC,Wang GS,Liao HF

更新日期：2008-01-01 00:00:00

abstract：:The in vitro antitumor activity of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, was compared with that of adriamycin (ADM) against human breast carcinomas inoculated into nude mice at the maximum tolerated dose (MTD) and clinically equivalent dose (CED). The plasma levels of NVB after intravenous inje...

journal_title：Anti-cancer drugs

authors： Tsuruo T,Inaba M,Tashiro T,Yamori T,Ohnishi Y,Ashizawa T,Sakai T,Kobayashi S,Gomi K

更新日期：1994-12-01 00:00:00

abstract：:Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

journal_title：Anti-cancer drugs

authors： He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

更新日期：2009-10-01 00:00:00

abstract：:Gastrointestinal stromal tumors (GIST) are the most common malignant mesenchymal tumors of the gastrointestinal tract. The principal treatment modality for primary GIST is surgery whereas for metastatic GIST, imatinib has an established role. In patients with locally advanced and metastatic GIST, the role of surgery i...

journal_title：Anti-cancer drugs

authors： Mearadji A,den Bakker MA,van Geel AN,Eggermont AM,Sleijfer S,Verweij J,de Wilt JH,Verhoef C

更新日期：2008-07-01 00:00:00

abstract：:Antibody-cytokine fusion proteins (also called 'immunocytokines') represent an emerging class of biopharmaceutical products, which are being considered for cancer immunotherapy. When used as single agents, pro-inflammatory immunocytokines are rarely capable of inducing complete and durable cancer regression in mouse m...

journal_title：Anti-cancer drugs

authors： Corbellari R,Nadal L,Villa A,Neri D,De Luca R

更新日期：2020-09-01 00:00:00

abstract：:Topical treatment of skin metastases with a cytotoxic agent is attractive for its easy self-administration and absence of major systemic interference. Miltefosine exerts its cytotoxicity by acting on cell membrane phospholipids and can be administered topically. Twenty breast cancer patients with progression of skin m...

journal_title：Anti-cancer drugs

authors： Smorenburg CH,Seynaeve C,Bontenbal M,Planting AS,Sindermann H,Verweij J

更新日期：2000-11-01 00:00:00

abstract：:The aim of this study was to evaluate whether radiolabeled iodoerythronitroimidazole (IETNIM) could predict the radiosensitization effect on tumors. Tumor-bearing mice were irradiated at a dose of 25, 31 and 37 Gy after the injection of IETNIM. They were also exposed to 37 Gy radiation at 35, 70, 140 and 240 min after...

journal_title：Anti-cancer drugs

authors： Inoue T,Yang DJ,Wallace S,Cherif A,Tansey W,Kim EE,Hunter N,Milross CG,Milas L,Podoloff DA

更新日期：1996-11-01 00:00:00